
News|Articles|May 1, 2007
Pipeline preview
The latest FDA action (through May 2007) related to armodafinil (Nuvigil), tacrolimus (Prograf), sipuleucel-T (Provenge), Etoricoxib (Arcoxia), AZD-103/ELND005 (Transition), rNAPc2, Satraplatin, and Ganciclovir
Advertisement
Key Points
• Pipeline preview
Approvable designations
Recommendation for approval
Fast-track designations
Priority review
Orphan drug designation
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
Key Takeaways, Study Limitations, and the Broader Implications of CROWN for Patients, Providers, and Payers
5
































